To Get Help Now
Click Here
 
Today's Date:

Actos Bladder Cancer Trial Underway in Nevada

AddThis Social Bookmark Button

A jury in Las Vegas, Nevada has been hearing arguments over safety issues associated with Takeda Pharmaceuticals’ type 2 diabetes medication, Actos.

The trial began on August 27, 2015 and is being heard before Judge Jerry Wiese in the Supreme Court of the State of Nevada, a consolidated case on behalf of a living plaintiff and the widow of a deceased man. Both men had been taking Actos (pioglitazone) and developed bladder cancer, which they allege was caused by the drug. Counsel for the plaintiffs will likely seek $2 billion in damages for the living man and for the widow.

Actos is typically prescribed, along with diet and exercise to individuals diagnosed with type 2 diabetes. If blood sugar levels are not controlled, a person with diabetes can suffer serious health consequences including blindness, nerve and kidney damage, and heart disease. Actos is intended to stabilize the unusually high blood sugar associated with the disease. But an increasing number of people who have taken Actos allege that the drug led to their bladder cancer.

Bladder cancer is an aggressive cancer that often recurs, even after years of remission. As with other cancers, treatment typically includes chemotherapy and radiation, as well as surgery and other medications. Plaintiffs involved in the Las Vegas Actos trial claim that Takeda knew of the Actos risks but did not appropriately inform patients, physicians, and others in the health care community.

At the start of the trial, Judge Wiese informed the jury that Takeda intentionally destroyed documents related to Actos cases. He said the jury could presume that the destroyed documents would have contributed to the two plaintiffs’ case. Similar instructions were given to a jury in an Actos bladder cancer trial in 2014. Attorneys for the plaintiffs pointed out that evidence was intentionally destroyed and that the hard drives from computers of eight Takeda executives were compromised, even after the court had instructed the company to preserve that specific evidence.

In opening remarks, an attorney read the following: “Takeda Pharmaceuticals already acknowledged they have no ability to rebut the presumption that the evidence they destroyed, on a massive scale, was damning. To put it into perspective, they could have filled a football stadium with the amount of evidence they destroyed if it were printed on paper.”

Nationwide, around 8,000 plaintiffs have filed lawsuits against Takeda Pharmaceuticals over Actos. In 2014, a Louisiana jury found Takeda liable for $9 billion after agreeing with the plaintiff that Takeda intentionally concealed health risks associated with Actos. A judge later reduced the award by 99.6 percent and found Takeda liable for $36.8 million. Court dockets reveal that there are over 3,500 Actos lawsuits consolidated before U.S. District Judge Rebecca Doherty in Lafayette, Louisiana for pretrial proceedings. Court records show an additional 4,500 cases in state courts in Illinois, West Virginia, California, and Pennsylvania.

 

breakinglawsuitnews.com disclaimer: This article: Actos Bladder Cancer Trial Underway in Nevada was posted on Thursday, October 8th, 2015 at 11:51 am at breakinglawsuitnews.com and is filed under Defective Drug Lawsuits.

« »

Comments are closed.